Expression and Functional Role of CRIPTO-1 in Cutaneous Melanoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Aug 25

PMID 21863025

Citations 23

Authors

A De Luca

L Lamura

L Strizzi

C Roma

A DAntonio

N Margaryan

G Pirozzi

M-Y Hsu

G Botti

E Mari

M J C Hendrix

D S Salomon

N Normanno

Affiliations

Soon will be listed here.

Abstract

Background: CRIPTO-1 (CR-1) is involved in the pathogenesis and progression of human carcinoma of different histological origin. In this study we addressed the expression and the functional role of CR-1 in cutaneous melanoma.

Methods: Expression of CR-1 protein in melanomas and melanoma cell lines was assessed by immunohistochemistry, western blotting and/or flow cytometry. Levels of mRNA were evaluated by real-time PCR. Invasion assays were performed in Matrigel-coated modified Boyden chambers.

Results: Expression of CR-1 protein and/or mRNA was found in 16 out of 37 primary human cutaneous melanomas and in 12 out of 21 melanoma cell lines. Recombinant CR-1 protein activated in melanoma cells c-Src and, at lesser extent, Smad signalling. In addition, CR-1 significantly increased the invasive ability of melanoma cells that was prevented by treatment with either the ALK4 inhibitor SB-431542 or the c-Src inhibitor saracatinib (AZD0530). Anti-CR-1 siRNAs produced a significant inhibition of the growth and the invasive ability of melanoma cells. Finally, a close correlation was found in melanoma cells between the levels of expression of CR-1 and the effects of saracatinib on cell growth.

Conclusion: These data indicate that a significant fraction of cutaneous melanoma expresses CR-1 and that this growth factor is involved in the invasion and proliferation of melanoma cells.

Citing Articles

Human Cripto-1 and Cripto-3 Protein Expression in Normal and Malignant Settings That Conflicts with Established Conventions.

Cuttitta F, Garcia-Sanmartin J, Feng Y, Sunday M, Kim Y, Martinez A Cancers (Basel). 2024; 16(21).

PMID: 39518018 PMC: 11545644. DOI: 10.3390/cancers16213577.

Expression and prognostic value of Cripto-1 in early non-small cell lung cancer.

Zhong J, Li L, Zhang Q, Zou J, Liu W, Xu C Clin Respir J. 2023; 17(12):1203-1208.

PMID: 37528674 PMC: 10730460. DOI: 10.1111/crj.13680.

CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer.

Francescangeli F, De Angelis M, Rossi R, Sette G, Eramo A, Boe A Front Oncol. 2022; 12:830873.

PMID: 35719935 PMC: 9200964. DOI: 10.3389/fonc.2022.830873.

The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells.

Gallo M, Carotenuto M, Frezzetti D, Camerlingo R, Roma C, Bergantino F Cancers (Basel). 2022; 14(7).

PMID: 35406622 PMC: 8997927. DOI: 10.3390/cancers14071851.

Normal Skin Cells Increase Aggressiveness of Cutaneous Melanoma by Promoting Epithelial-to-Mesenchymal Transition via Nodal and Wnt Activity.

Untiveros G, Dezi L, Gillette M, Sidor J, Strizzi L Int J Mol Sci. 2021; 22(21).

PMID: 34769150 PMC: 8583838. DOI: 10.3390/ijms222111719.

References

Leonetti C, DAgnano I, Lozupone F, Valentini A, Geiser T, Zon G . Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. J Natl Cancer Inst. 1996; 88(7):419-29. DOI: 10.1093/jnci/88.7.419. View

Strizzi L, Bianco C, Hirota M, Watanabe K, Mancino M, Hamada S . Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice. J Pathol. 2006; 211(1):36-44. DOI: 10.1002/path.2083. View

Normanno N, Bianco C, De Luca A, Salomon D . The role of EGF-related peptides in tumor growth. Front Biosci. 2001; 6:D685-707. DOI: 10.2741/normano. View

Ciardiello F, Dono R, Kim N, Persico M, Salomon D . Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res. 1991; 51(3):1051-4. View

De Luca A, Casamassimi A, Selvam M, Losito S, Ciardiello F, Agrawal S . EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. Int J Cancer. 1999; 80(4):589-94. DOI: 10.1002/(sici)1097-0215(19990209)80:4<589::aid-ijc17>3.0.co;2-d. View

DAntonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A . Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol. 2002; 21(5):941-8. View

Blanchet M, Le Good J, Oorschot V, Baflast S, Minchiotti G, Klumperman J . Cripto localizes Nodal at the limiting membrane of early endosomes. Sci Signal. 2008; 1(45):ra13. DOI: 10.1126/scisignal.1165027. View

Eustace A, Crown J, Clynes M, ODonovan N . Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 2008; 6:53. PMC: 2569026. DOI: 10.1186/1479-5876-6-53. View

Sun Y, Strizzi L, Raafat A, Hirota M, Bianco C, Feigenbaum L . Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol. 2005; 167(2):585-97. PMC: 1603555. DOI: 10.1016/S0002-9440(10)63000-3. View

10.

Strizzi L, Postovit L, Margaryan N, Lipavsky A, Gadiot J, Blank C . Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol. 2009; 4(1):67-78. PMC: 2682534. DOI: 10.1586/17469872.4.1.67. View

11.

Buettner R, Mesa T, Vultur A, Lee F, Jove R . Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008; 6(11):1766-74. PMC: 2768340. DOI: 10.1158/1541-7786.MCR-08-0169. View

12.

Verschraegen C, GIOVANELLA B, MENDOZA J, Kozielski A, STEHLIN Jr J . Specific organ metastases of human melanoma cells injected into the arterial circulation of nude mice. Anticancer Res. 1991; 11(2):529-35. View

13.

Normanno N, De Luca A, Maiello M, Campiglio M, Napolitano M, Mancino M . The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2006; 207(2):420-7. DOI: 10.1002/jcp.20588. View

14.

Pirozzi G, Lombari V, Zanzi D, Ionna F, Lombardi M, Errico S . CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth. Int Immunol. 2000; 12(6):787-95. DOI: 10.1093/intimm/12.6.787. View

15.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A . Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002; 21(46):7001-10. DOI: 10.1038/sj.onc.1205859. View

16.

Barnekow A, Paul E, Schartl M . Expression of the c-src protooncogene in human skin tumors. Cancer Res. 1987; 47(1):235-40. View

17.

Strizzi L, Abbott D, Salomon D, Hendrix M . Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle. 2008; 7(13):1931-5. PMC: 2556902. DOI: 10.4161/cc.7.13.6236. View

18.

Qi J, Wang J, Romanyuk O, Siu C . Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell. 2005; 17(3):1261-72. PMC: 1382315. DOI: 10.1091/mbc.e05-10-0927. View

19.

Adkins H, Bianco C, Schiffer S, Rayhorn P, Zafari M, Cheung A . Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003; 112(4):575-87. PMC: 171388. DOI: 10.1172/JCI17788. View

20.

Gray P, Shani G, Aung K, Kelber J, Vale W . Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol. 2006; 26(24):9268-78. PMC: 1698529. DOI: 10.1128/MCB.01168-06. View